Dexamethasone Mitigates Neurological Adverse Effects from CD3 Binding Domains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-based cancer therapies, such as those using CD19xCD3 bispecific single-chain antibodies, often cause neurological and psychiatric adverse effects, which can be severe and limit their tolerability in patients.
Innovation Solution
Administering dexamethasone prior to and during the treatment with CD3 binding domains, particularly CD19xCD3 bispecific single-chain antibodies, to prevent or alleviate neurological adverse effects such as seizures, encephalopathy, and cerebral edema.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD3 binding domain therapy is administered to treat cancer, then therapeutic efficacy is improved, but neurological adverse effects worsen
Solution Approach 1:
The patent applies preliminary action by administering dexamethasone before the CD3 binding domain therapy to prevent neurological adverse effects. The glucocorticoid is given in advance to prepare the patient's system, reducing the risk of seizures, encephalopathy, and other neurological complications that would otherwise occur during antibody therapy.
Solution Approach 2:
The patent uses dexamethasone as an intermediary substance that mediates between the CD3 binding domain therapy and the patient's neurological system. The glucocorticoid acts as a protective intermediary that allows the therapeutic antibody to exert its cancer-killing effect while blocking the harmful neurological side effects through its anti-inflammatory and immunomodulatory properties.
2Reliability
If CD3 binding domain therapy is administered to achieve cancer cell lysis, then tumor regression is improved, but patient tolerability worsens
Solution Approach 1:
The patent applies preliminary action by administering dexamethasone before the CD3 binding domain therapy to prevent neurological adverse effects. The glucocorticoid is given in advance to prepare the patient's system, reducing the risk of seizures, encephalopathy, and other neurological complications that would otherwise occur during antibody therapy.
Solution Approach 2:
The patent converts the harmful neurological side effects into a benefit by using dexamethasone to trigger controlled cytokine release and immune modulation. The glucocorticoid transforms the potentially dangerous neurological reactions into a manageable immune response that enhances tumor cell lysis while reducing patient suffering and improving tolerability.
Data Source
AI summary
The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.